A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
In the clinical utilization of sunitinib, vigilant monitoring of potential adverse reactions is imperative during the initial phase of drug administration. In addition to the documented adverse reactions outlined in the drug specification, healthcare providers should remain attentive to potential adverse reactions such as pleural effusion, ascites, and tumor development.
Authors
- Xiangning Fu (ORCID: https://orcid.org/0000-0003-4670-1438)
- Wei Chen (ORCID: https://orcid.org/0009-0007-4260-1794)
- Chenxi Zeng
- Wen‐Bin Zou
- Yang Han (ORCID: https://orcid.org/0009-0004-6237-5630)
- Yu Xi (ORCID: https://orcid.org/0009-0005-3022-9281)
Institutions
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e37543
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- National Natural Science Foundation of China